UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The Journal of clinical investigation, ISSN 0021-9738, 09/2008, Volume 118, Issue 9, pp. 3038 - 3050
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Protein Kinases - metabolism | Cell Proliferation | Antigens, CD34 - biosynthesis | Humans | Phosphatidylinositol 3-Kinases - metabolism | Gene Expression Regulation, Leukemic | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Animals | Antigens, CD19 - biosynthesis | Cell Transformation, Neoplastic | Models, Biological | Burkitt Lymphoma - genetics | Cell Line, Tumor | Antineoplastic Agents - pharmacology | Mice | TOR Serine-Threonine Kinases | Fusion Proteins, bcr-abl - metabolism | Cell proliferation | Control | Translocation (Genetics) | Physiological aspects | Genetic aspects | Research | Chronic myeloid leukemia | Risk factors | Prevention | Leukemia | Index Medicus | Abridged Index Medicus
Journal Article
Clinical cancer research, ISSN 1078-0432, 02/2012, Volume 18, Issue 4, pp. 930 - 937
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Antineoplastic agents | Chromosome aberrations | Pharmacology. Drug treatments | Medical genetics | Humans | Translational Medical Research | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Agents - therapeutic use | Animals | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Antineoplastic Agents - pharmacology | Mice | Protein Kinase Inhibitors - pharmacology | Fusion Proteins, bcr-abl - metabolism | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 12/2007, Volume 110, Issue 12, pp. 4055 - 4063
Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Chemotherapy | Pharmacology. Drug treatments | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Antineoplastic agents | Protein-Tyrosine Kinases - metabolism | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Drug Resistance, Neoplasm | Neoplasm Proteins - antagonists & inhibitors | Piperazines - chemistry | Thiazoles - therapeutic use | Neoplasm Proteins - metabolism | Pyrimidines - chemistry | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - chemistry | Fusion Proteins, bcr-abl | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Protein-Serine-Threonine Kinases - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Dasatinib | Quinone Reductases - metabolism | Piperazines - therapeutic use | Discoidin Domain Receptor 1 | Pyrimidines - pharmacology | Receptor Protein-Tyrosine Kinases - metabolism | Imatinib Mesylate | Piperazines - pharmacology | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinone Reductases - antagonists & inhibitors | K562 Cells | Proteomics | Thiazoles - chemistry | Protein Kinase Inhibitors - pharmacology | Thiazoles - pharmacology | Benzamides | Drug Screening Assays, Antitumor | Protein-Tyrosine Kinases - antagonists & inhibitors | Index Medicus | Abridged Index Medicus
Journal Article
Cancer cell, ISSN 1535-6108, 2009, Volume 16, Issue 5, pp. 401 - 412
CHEMBIO | HUMDISEASE | Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Pyridazines - pharmacology | Protein Kinase Inhibitors - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Antineoplastic Agents - pharmacology | Fusion Proteins, bcr-abl - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Proto-Oncogene Proteins c-abl - genetics | Cell Growth Processes - drug effects | Proto-Oncogene Proteins c-abl - chemistry | Models, Molecular | Imidazoles - pharmacology | Antineoplastic Agents - chemistry | Mice, SCID | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Animals | Signal Transduction - drug effects | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Proto-Oncogene Proteins c-abl - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Fusion Proteins, bcr-abl - metabolism | Chronic myeloid leukemia | BCR protein | Imatinib | Mutagenesis | Abl protein | Mutation | Fusion protein | Tumors | Index Medicus | imatinib resistance | dasatinib | nilotinib | compound mutation
Journal Article
Leukemia, ISSN 0887-6924, 2019, Volume 33, Issue 7, pp. 1583 - 1597
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Leukemia, Large Granular Lymphocytic - drug therapy | Cell Proliferation | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | STAT5 Transcription Factor - genetics | STAT5 Transcription Factor - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Tumor Suppressor Proteins - genetics | Antineoplastic Agents - pharmacology | Leukemia, Large Granular Lymphocytic - pathology | Tumor Suppressor Proteins - metabolism | Interferons - pharmacology | Survival Rate | Mice, SCID | Cell Transformation, Neoplastic - metabolism | Mice, Knockout | Xenograft Model Antitumor Assays | Fusion Proteins, bcr-abl - genetics | Animals | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Leukemia, Large Granular Lymphocytic - metabolism | Mice, Inbred NOD | Mice | Cell Transformation, Neoplastic - drug effects | Mutation | Cell Transformation, Neoplastic - pathology | Fusion Proteins, bcr-abl - metabolism | RNA sequencing | Usage | Gene mutations | Leukemia | Development and progression | Genetic aspects | Cellular signal transduction | Research | BCR protein | Biotechnology | Transformation | Deregulation | Transcription factors | Profiling | Transcription | Abl gene | BCR gene | Kinases | Gene sequencing | α-Interferon | Signal transduction | Janus kinase | Transducers | Cell survival | Colonies | Inhibition (psychology) | Stat5 protein | Ribonucleic acid--RNA | Disease control | Survival | Hemopoiesis | Lymphocytes B | γ-Interferon | Leukemogenesis | Interferon | Tumors | Index Medicus | Cell signalling | Acute lymphocytic leukaemia
Journal Article
Clinical cancer research, ISSN 1078-0432, 05/2011, Volume 17, Issue 10, pp. 3219 - 3232
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Antineoplastic agents | Chromosome aberrations | Pharmacology. Drug treatments | Medical genetics | Piperazines - administration & dosage | Humans | Histone Deacetylase Inhibitors - administration & dosage | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Indazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Adult | Piperazines - therapeutic use | Mice, SCID | Imatinib Mesylate | Piperazines - pharmacology | Drug Synergism | Indazoles - pharmacology | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Histone Deacetylase Inhibitors - pharmacology | Mice | Mice, Inbred BALB C | Protein Kinase Inhibitors - pharmacology | Benzamides | Fusion Proteins, bcr-abl - metabolism | Drug Resistance, Neoplasm - drug effects | Index Medicus
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 27, pp. 43662 - 43677
BCR-ABL+ human leukemia | Icaritin (SNG162 and SNG1153) | ERa36 | Leukemic stem cells | Tyrosine kinase inhibitors | Oncology | Life Sciences & Biomedicine | Science & Technology | Cell Biology | Cell Membrane | Phosphorylation | Neoplastic Stem Cells - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Chromans - pharmacology | Neoplastic Stem Cells - metabolism | Estrogen Receptor alpha - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality | Gene Expression | Protein Transport | Fusion Proteins, bcr-abl - genetics | Estrogen Receptor alpha - genetics | Models, Biological | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Protein Binding | Cell Proliferation - drug effects | Protein Kinase Inhibitors - pharmacology | Mutation | GRB2 Adaptor Protein - metabolism | Fusion Proteins, bcr-abl - metabolism | Amino Acid Substitution | Index Medicus
Journal Article
Leukemia, ISSN 0887-6924, 07/2008, Volume 22, Issue 7, pp. 1402 - 1409
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | Hematologic and hematopoietic diseases | Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis | Biological and medical sciences | Medical sciences | Chromosome aberrations | Medical genetics | Blast Crisis - drug therapy | Caspase 9 - metabolism | Immunoprecipitation | Leukemia - pathology | Apoptosis - drug effects | Humans | Caspase 3 - metabolism | Leukemia - metabolism | Extracellular Signal-Regulated MAP Kinases - metabolism | Novobiocin - pharmacology | Cytochromes c - metabolism | Leukemia - drug therapy | Pyrimidines - pharmacology | Lactams, Macrocyclic - pharmacology | Imatinib Mesylate | Piperazines - pharmacology | Proteasome Endopeptidase Complex - physiology | Benzoquinones - pharmacology | Fusion Proteins, bcr-abl - analysis | HSP90 Heat-Shock Proteins - antagonists & inhibitors | K562 Cells | HL-60 Cells | HSP90 Heat-Shock Proteins - metabolism | Cell Proliferation - drug effects | Benzamides | Fusion Proteins, bcr-abl - metabolism | Care and treatment | Heat shock proteins | Genetic aspects | Acute lymphocytic leukemia | Diagnosis | Health aspects | Philadelphia chromosome | Index Medicus
Journal Article
Leukemia, ISSN 0887-6924, 04/2017, Volume 31, Issue 10, pp. 2065 - 2074
Oncology | Life Sciences & Biomedicine | Hematology | Science & Technology | RNA, Small Interfering - genetics | Blast Crisis - drug therapy | Coculture Techniques | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Neoplasm Proteins - antagonists & inhibitors | Molecular Targeted Therapy | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Mesenchymal Stromal Cells - cytology | Leukemia, Myeloid, Accelerated Phase - pathology | RNA Interference | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Female | Pyrimidinones - pharmacology | Tumor Cells, Cultured | Neoplasm Proteins - genetics | Leukemia, Myeloid, Accelerated Phase - drug therapy | Blast Crisis - pathology | Neoplasm Proteins - biosynthesis | Pyrimidinones - therapeutic use | Pyrimidines - pharmacology | Random Allocation | Mice, SCID | beta Catenin - genetics | Mice, Knockout | Drug Synergism | Xenograft Model Antitumor Assays | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Animals | Wnt Signaling Pathway - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrimidines - therapeutic use | beta Catenin - antagonists & inhibitors | Fusion Proteins, bcr-abl - antagonists & inhibitors | Mice, Inbred NOD | Drug Resistance, Neoplasm - drug effects | Index Medicus | Original
Journal Article
Nature reviews. Drug discovery, ISSN 1474-1776, 10/2007, Volume 6, Issue 10, pp. 834 - 848
Pharmacology & Pharmacy | Life Sciences & Biomedicine | Biotechnology & Applied Microbiology | Science & Technology | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Models, Molecular | Antineoplastic Agents - therapeutic use | Clinical Trials as Topic | Antineoplastic Agents - chemistry | Point Mutation | Drug Resistance, Neoplasm - genetics | Protein Kinase Inhibitors - chemistry | Protein-Tyrosine Kinases - genetics | Animals | Fusion Proteins, bcr-abl | Protein Kinase Inhibitors - therapeutic use | Drug Design | Protein Binding | Antineoplastic Agents - pharmacology | Protein Kinase Inhibitors - pharmacology | Drug Resistance, Neoplasm - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Development and progression | Care and treatment | Prognosis | Chronic myeloid leukemia | Index Medicus
Journal Article